# Integrated Assessment of Drugs and Interventional Devices in the Management of Acute Myocardial Infarction, Refractory Angina, and Heart Failure: A Clinical Outcome-Based Study

## TL;DR

This study found that device-based treatments improved outcomes more than drugs for patients with heart conditions like heart failure and heart attacks.

## Contribution

The study provides new evidence that device-based therapies outperform pharmacological treatments in managing specific heart conditions.

## Key findings

- Device-based interventions reduced major adverse cardiovascular events compared to drugs (16.2% vs. 33.3%).
- Device users showed faster symptom improvement and lower heart failure hospitalization rates.
- Device therapy led to greater decreases in pulmonary artery pressure and better event-free survival.

## Abstract

Aim

This study aims to evaluate the clinical outcomes of pharmacological and interventional therapies in managing heart failure (HF), refractory angina (RA), and acute myocardial infarction (AMI) to enhance survival, recovery, and quality of life.

Methodology

This prospective observational study included 67 patients with acute myocardial infarction, refractory angina, or congestive heart failure (CHF) to compare pharmaceutical and device-based therapy. Patients were categorized based on diagnosis and therapy modality, with procedures comprising percutaneous coronary intervention (PCI), coronary sinus reducers (CSR), and pulmonary artery pressure (PAP) monitors. Outcomes, including major adverse cardiac events (MACE), symptom ratings, and hemodynamics, were evaluated over 24 months. Data were examined statistically utilizing SPSS version 26 (IBM Corp., Armonk, NY), with significance established at p < 0.05. No randomization or matching was applied; allocation reflected routine clinical decision-making.

Results

The findings indicated that device-based interventions were more effective than pharmacological therapy across all categories in the cohort study of 67 individuals with AMI, RA, and CHF. The fundamental characteristics were analogous. Individuals utilizing the device had a significantly reduced risk of major adverse cardiovascular events (16.2% against 33.3%, p = 0.028), experienced expedited symptom improvement (for instance, New York Heart Association (NYHA) class I in 64.3% compared to 42.8% in AMI, p = 0.037), and demonstrated a decreased likelihood of hospitalization due to heart failure (10% versus 27.3%, p = 0.045). The device group observed significant alterations in their hemodynamic parameters, notably a more pronounced decrease in PAP (p < 0.01). The device group had a superior event-free survival rate (p = 0.034), particularly in patients with AMI and CHF.

Conclusion

In conclusion, this study suggests that device-based therapies were associated with more favorable clinical outcomes compared to pharmacological treatments among patients with acute myocardial infarction, refractory angina, and congestive heart failure. Despite limitations such as the modest sample size and observational design, the findings highlight the need for larger, randomized trials to confirm these associations.